Bortezomib, a proteasome inhibitor, attenuates angiotensin II-induced hypertension and aortic remodeling in rats.
Hypertension is a highly prevalent disorder and a major risk factor for cardiovascular diseases. Hypertensive vascular remodeling is the pathological mal-adaption of blood vessels to the hypertensive condition that contributes to further development of high blood pressure and end-organ damage. Hyper...
Main Authors: | Shuai Li, Xuejun Wang, Yifan Li, Curtis K Kost, Douglas S Martin |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2013-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC3813683?pdf=render |
Similar Items
-
Activity probe for in vivo profiling of the specificity of proteasome inhibitor bortezomib.
by: Berkers, C, et al.
Published: (2005) -
Metformin Induces Resistance of Cancer Cells to the Proteasome Inhibitor Bortezomib
by: Camille Schlesser, et al.
Published: (2022-05-01) -
Trypanocidal activity of the proteasome inhibitor and anti-cancer drug bortezomib
by: Wang Xia, et al.
Published: (2009-07-01) -
Biomimetic platelet nanoparticles encapsulated with proteasome inhibitor bortezomib for multiple myeloma treatment
by: Guangtao Gao, et al.
Published: (2023-12-01) -
The Proteasome Inhibitor Bortezomib Induces Apoptosis and Activation in Gel-Filtered Human Platelets
by: Harriet Ghansah, et al.
Published: (2021-08-01)